

# Rahul Aggarwal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/958773/publications.pdf>

Version: 2024-02-01

66  
papers

3,572  
citations

236925

25  
h-index

149698

56  
g-index

67  
all docs

67  
docs citations

67  
times ranked

5706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical translation of hyperpolarized <sup>13</sup> C pyruvate and urea MRI for simultaneous metabolic and perfusion imaging. <i>Magnetic Resonance in Medicine</i> , 2022, 87, 138-149.	3.0	23
2	Hyperpolarized 1-[ <sup>13</sup> C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer. <i>European Urology</i> , 2022, 81, 219-221.	1.9	17
3	In Vivo Profiling with <sup>18</sup> F-YJH08 Reveals Diverse Tissue Patterns of Antagonist/Glucocorticoid Receptor Interactions. <i>Molecular Pharmaceutics</i> , 2022, 19, 704-709.	4.6	2
4	Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100182.	2.1	0
5	A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. <i>Cancer Research Communications</i> , 2022, 2, 570-576.	1.7	1
6	CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. <i>Clinical Cancer Research</i> , 2022, 28, 3066-3075.	7.0	10
7	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3979-3989.	7.0	8
8	Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 81-87.	3.9	14
9	Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	8
10	Resistance to Androgen Deprivation Leads to Altered Metabolism in Human and Murine Prostate Cancer Cell and Tumor Models. <i>Metabolites</i> , 2021, 11, 139.	2.9	13
11	Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. <i>Scientific Reports</i> , 2021, 11, 5040.	3.3	40
12	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. <i>JCO Precision Oncology</i> , 2021, 5, 710-725.	3.0	6
13	Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.		21
14	Differential Activity of PARP Inhibitors in <i>BRCA1</i> - Versus <i>BRCA2</i> -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1200-1220.	3.0	17
15	Specialized computational methods for denoising, B 1 correction, and kinetic modeling in hyperpolarized <sup>13</sup> C MR EPSI studies of liver tumors. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 2402-2411.	3.0	6
16	Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3130-3143.	1.4	9
17	A phase I/II study of rovalpituzumab tesirine in delta-like 3 expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.	5.4	27
18	A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 730.e9-730.e15.	1.6	2

#	ARTICLE	IF	CITATIONS
19	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.	12.8	51
20	Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.	2.9	1
21	Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. <i>Molecular Imaging and Biology</i> , 2020, 22, 208-216.	2.6	16
22	Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 269-276.	3.9	68
23	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
24	Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	3.2	19
25	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	13.2	45
26	Tipifarnib in recurrent, metastatic HRAS mutant salivary gland cancer. <i>Cancer</i> , 2020, 126, 3972-3981.	4.1	34
27	Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. <i>Journal of Magnetic Resonance</i> , 2019, 301, 73-79.	2.1	27
28	Reply to A. Dalla Volta et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-352.	1.6	0
29	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.	1.9	104
30	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.	3.9	66
31	Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.	5.0	35
32	Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e92-e96.	1.9	19
33	Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 2702-2709.	3.0	65
34	Defining the Prognostic and Predictive Impact of Germline DNA Repair Mutations in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 73, 694-695.	1.9	0
35	Technique development of 3D dynamic CS-EPSI for hyperpolarized <sup>13</sup> C pyruvate MR molecular imaging of human prostate cancer. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 2062-2072.	3.0	47
36	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone-and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, e64-e64.	3.7	25

#	ARTICLE	IF	CITATIONS
37	A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets. <i>European Urology</i> , 2018, 73, 306-307.	1.9	6
38	Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. <i>European Urology</i> , 2018, 73, 845-846.	1.9	4
39	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.	1.6	477
40	Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	43
41	Investigation of analysis methods for hyperpolarized <sup>13</sup> C-pyruvate metabolic MRI in prostate cancer patients. <i>NMR in Biomedicine</i> , 2018, 31, e3997.	2.8	77
42	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.	28.9	459
43	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 78-82.	5.4	74
44	A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e7-149.e13.	1.6	7
45	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. <i>European Urology</i> , 2017, 72, 34-42.	1.9	179
46	Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.	9.4	223
47	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1221-1229.	3.4	27
48	CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1073-1081.e1.	0.5	30
49	Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2017, 18, 1436-1437.	10.7	1
50	Hyperpolarized 1-[ <sup>13</sup> C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer. <i>European Urology</i> , 2017, 72, 1028-1029.	1.9	127
51	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	288
52	<sup>68</sup> Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. <i>Journal of Nuclear Medicine</i> , 2017, 58, 81-84.	5.0	166
53	Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. <i>Breast Cancer Research</i> , 2017, 19, 107.	5.0	19
54	Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. , 2017, 5, 75.		52

#	ARTICLE	IF	CITATIONS
55	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 71447-71455.	1.8	23
56	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundationâ€œSupported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.	3.1	12
57	A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 946-951.	2.6	33
58	Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?. <i>European Urology</i> , 2016, 70, 445-446.	1.9	0
59	Approaches to minimize castration in the treatment of advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 368-374.	1.6	6
60	The changing role of imaging in clinical care. <i>Nature Reviews Urology</i> , 2014, 11, 75-77.	3.8	3
61	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e167-e172.	1.9	32
62	Impact of patient ethnicity on the metabolic and immunologic effects of PI3Kâ€œmTOR pathway inhibition in patients with solid tumor malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 359-365.	2.3	8
63	Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 719-726.	4.9	141
64	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrateâ€œresistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	4.1	17
65	Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment. <i>Oncologist</i> , 2011, 16, 264-275.	3.7	27
66	The Mechanism of Action of Estrogen in Castration-Resistant Prostate Cancer: Clues From Hormone Levels. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E71-E76.	1.9	28